Immunotherapy + targeted therapy for CRC shows positive phase II results

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Three years ago, researchers from Memorial Sloan Kettering Cancer Center published stunning results: For the 5% of rectal cancer patients whose tumors are mismatch-repair deficient, neoadjuvant dostarlimab-gxly (Jemperli) has the makings of a silver bullet.

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

When Kelly Spill was eight months pregnant, she experienced some constipation and noticed blood in her stool. Her OBGYN wasn’t worried.

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a phase III clinical trial by researchers at City of Hope.

May 02, 2025

Vol.51 No.17

Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

April 25, 2025

Vol.51 No.16

By Richard M. Goldberg

Clinical

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Immunotherapy has changed the course of blood cancers and melanomas, but is stubbornly ineffective for the treatment of most epithelial solid cancers—the cancers that kill about 90% of the more than 600,000 Americans who die of cancer each year.

Disasters likely delay early cancer diagnoses, study shows

Rates of colorectal cancer diagnoses dropped during and shortly after Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, according to a recent analysis led by investigators at the University of Puerto Rico.

April 18, 2025

Vol.51 No.15

Immunotherapy + targeted therapy for CRC shows positive phase II results

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Regulation must keep up with scientific advances

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Disasters likely delay early cancer diagnoses, study shows

Renew today!

Subscriber content

Never miss an issue!

Login

Immunotherapy + targeted therapy for CRC shows positive phase II results

YOU MAY BE INTERESTED IN

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Regulation must keep up with scientific advances

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Disasters likely delay early cancer diagnoses, study shows

Never miss an issue!

Login

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child